Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Up 129.5% in February

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 586,941 shares, a growth of 129.5% from the January 29th total of 255,701 shares. Based on an average trading volume of 256,977 shares, the short-interest ratio is presently 2.3 days. Approximately 3.8% of the company’s stock are sold short. Approximately 3.8% of the company’s stock are sold short. Based on an average trading volume of 256,977 shares, the short-interest ratio is presently 2.3 days.

Analysts Set New Price Targets

MRKR has been the topic of several research reports. UBS Group restated a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. Zacks Research cut shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Wall Street Zen raised shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. HC Wainwright began coverage on Marker Therapeutics in a research report on Monday, December 8th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Marker Therapeutics Price Performance

Marker Therapeutics stock opened at $1.58 on Friday. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07. The business’s fifty day moving average is $1.66 and its 200 day moving average is $1.27. The stock has a market capitalization of $26.34 million, a PE ratio of -1.28 and a beta of 1.44.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new stake in Marker Therapeutics in the fourth quarter worth approximately $222,000. Geode Capital Management LLC boosted its stake in shares of Marker Therapeutics by 35.3% in the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock worth $194,000 after buying an additional 34,028 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Marker Therapeutics by 16.4% in the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after buying an additional 17,400 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after acquiring an additional 13,340 shares during the period. Finally, LPL Financial LLC increased its position in Marker Therapeutics by 41.7% during the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after acquiring an additional 24,500 shares during the last quarter. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.